Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study
Jinhong Zhu, Jinfeng Zhang, Xiaodong Ling, Changhong Wang, Yingnan Yang, Yangzhong Xin, Hao Jiang, Hao Liang, Luquan Zhang, Xionghai Qin, Jingle Lei, Chengyuan Fang, Xinxin Yang, Yuning Wang, Wei Meng, Xiaoyuan Wang, Hongxue Meng, Jianqun Ma · 2025
Read Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study by Jinhong Zhu, Jinfeng Zhang, Xiaodong Ling, Changhong Wang, Yingnan Yang, Yangzhong Xin, Hao Jiang, Hao Liang, Luquan Zhang, Xionghai Qin, Jingle Lei, Chengyuan Fang, Xinxin Yang, Yuning Wang, Wei Meng, Xiaoyuan Wang, Hongxue Meng, Jianqun Ma (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12857139.txt.
Description
Jinhong Zhu and co-authors test pre-surgery combination therapy for throat cancer in a 2025 trial. One hundred forty-one patients had esophageal cancer deemed inoperable at entry. They received an immune drug plus two chemotherapy drugs every three weeks, hoping the tumors would shrink enough for surgery.
About half the patients converted to surgery, and all their tumor edges came out clean. One in five surgical patients showed no cancer left in the removed tissue. One-year survival reached about seventy-nine percent, and operated patients lived far longer. Side effects hit three quarters of patients but stayed mostly mild. Readers get a conversion path for once-inoperable disease.
Catalog record
| CREATOR | Jinhong Zhu, Jinfeng Zhang, Xiaodong Ling, Changhong Wang, Yingnan Yang, Yangzhong Xin, Hao Jiang, Hao Liang, Luquan Zhang, Xionghai Qin, Jingle Lei, Chengyuan Fang, Xinxin Yang, Yuning Wang, Wei Meng, Xiaoyuan Wang, Hongxue Meng, Jianqun Ma |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |